From Supplier to Public Health Player: The Changing Role of Biopharma Companies
Access challenges to cell and gene therapy are well documented. Precision’s Christina Poschen and David Carr discuss how some innovative manufacturers are moving away from the role of being purely a researcher and manufacturer and toward involvement at the point of diagnosis through manufacturing and delivery to patient access support in order to address those challenges head on.
2020 Priorities Include Inter-Operability, Cybersecurity and SDoH
Who typically has responsibility for Identity and Access Management within health plan organizations, and how does this role impact or protect their healthcare analytics objectives? Precision’s Dominic Galante contributes to the Thought Leaders Corner in this month’s Care Analytics News.
Precision Medicine Group has a new website!
With the discipline of precision medicine as the foundation, Precision Medicine Group has Precision for Medicine’s next-gen clinical development and Precision Value & Health’s industry leading commercialization working together to accelerate the delivery of life science innovations. Visit the new Precision Medicine Group website, and see how we’re moving science closer to health.
Webinar: Using HEOR Methods to Reduce Health Inequalities
Current social and political events have brought renewed attention to the levels of systemic inequalities faced by millions of minorities in the United States and around the world. Adding to the discussion, Precision will explore how innovative health economics and outcomes research (HEOR) methods can be leveraged to quantify the full value new treatments that improve health outcomes for underserved communities.
Creating Incentives To Narrow The Gap In Health Outcomes: Expanding Value Assessment To Incorporate Health Inequality
Over the past decade, healthcare has slowly been moving from a focus on volume to value based healthcare. With the COVID-19 pandemic, compelling aspects of alternative payment models (APM) are causing providers, payers, and pharmaceutical manufacturers to take notice. Precision’s Elizabeth Oyekan identifies four emerging trends in APM practices that are enabling APMs to be better prepared to deliver high-quality and more affordable care during the COVID-19 pandemic.
Webinar: Gene Therapies In Hemophilia
As the first ‘big wave’ in the gene therapy space, onetime potentially curative treatments for hemophilia present a potential revolution for many thousands of patients. However, so far, gene therapies have targeted smaller indications and the prospect of treating much higher numbers at the price benchmarks already set may prove challenging for payers and health systems to provide access.
Webinar: Optimizing Product Launch Market Access strategy and Gross-to-Net Modeling
Join Precision and Akara Group on Thursday, 8/6, 2020 | 12:00 PM EDT – 1:00 PM EDT for a special live, online discussion of best practices for pre-launch commercialization activities. Featuring Precision’s Brett DiNatale, learn about the latest advances in data, analytics, and technology, and understand how these latest advances can be used to improve decisions that impact GTN.
PRECISIONvalue is an MM&M finalist!
We’re excited to announce that PRECISIONvalue has been shortlisted for a 2020 MM&M award along with Takeda Oncology in the Use of Market Access Marketing category! And congratulations to our colleagues at PRECISIONeffect for their finalist nomination in the TV Advertising Campaign category.
Virtual Pharma-Payer Negotiations May Require More Persistence in COVID-19 Era
COVID-19 led to the cancellation of in-person meetings and conferences where pharmaceutical manufacturers connect with payers. Precision’s Andrew Cournoyer discusses our research results on the effects of the shift to virtual negotiations between pharma and payers, and the challenges they face going forward.
Could the COVID-19 Pandemic Create New Opportunities for the Adoption of APMs and Be a Catalyst for the Movement From Volume to Value?
Over the past decade, healthcare has slowly been moving from a focus on volume to value based healthcare. With the COVID-19 pandemic, compelling aspects of alternative payment models (APM) are causing providers, payers, and pharmaceutical manufacturers to take notice. Precision’s Elizabeth Oyekan identifies four emerging trends in APM practices that are enabling APMs to be better prepared to deliver high-quality and more affordable care during the COVID-19 pandemic.